Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-12-08 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
股东会议事规则（2025年12月）
Governance Information Classification · 100% confidence The document is titled as "股东会议事规则" which translates to "Shareholders Meeting Rules" or "Rules of Procedure for Shareholders' Meetings". It details the rules and procedures for convening, conducting, and voting in shareholders' meetings, including the rights and responsibilities of shareholders, the role of the board, and legal compliance. It does not contain financial statements, audit opinions, or financial results. It is a governance-related document outlining internal rules and procedures for shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full document, not a brief announcement or notice.
2025-12-08 Chinese
独立董事工作制度（2025年12月）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, qualifications, and operational procedures for independent directors of the company 迈威（上海）生物科技股份有限公司. It references relevant laws, regulations, and stock exchange rules, and outlines governance practices related to board members. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and board management practices, fitting the definition of Governance Information (CGR). The document length is 8492 characters, which is substantive and not a brief announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2025-12-08 Chinese
迈威生物关于归还前次临时补充流动资金的闲置募集资金并继续使用部分闲置募集资金临时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the return of previously used idle raised funds for temporary working capital and the continued use of some idle raised funds for the same purpose. It details the amounts, approvals by the board and supervisory committee, compliance with regulatory rules, and includes opinions from the supervisory board and the sponsoring institution. The document is relatively short (3226 characters) and primarily serves as a formal disclosure of financing and capital usage activities related to raised funds. It does not contain comprehensive financial statements or detailed financial performance data. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-12-08 Chinese
公司章程（2025年12月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 迈威(上海)生物科技股份有限公司, covering company structure, shareholder rights, board and management roles, share issuance and transfer rules, shareholder meeting procedures, and other governance matters. It references Chinese company law and securities regulations, and includes detailed provisions on shareholder meetings, board responsibilities, share capital, and corporate governance. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a proxy statement or voting results announcement. The content is focused on governance rules and company bylaws, which fits the definition of Governance Information (CGR). The document length is substantial and contains the full text of the governance rules, not just an announcement or summary. Therefore, the appropriate classification is Governance Information (CGR).
2025-12-08 Chinese
对外担保管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '迈威（上海）生物科技股份有限公司 对外担保管理制度' which translates to 'Maiwei (Shanghai) Biotechnology Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the procedures, responsibilities, and legal compliance requirements for the company's external guarantees. It includes chapters on general provisions, compliance rules, application and review procedures, daily management and risk control, legal responsibilities, and appendices. There is no indication that this is a financial report, audit report, earnings release, or any form of shareholder meeting material. It is not a regulatory filing or announcement but rather a governance or internal control document. The content focuses on governance practices related to external guarantees, which fits best under Governance Information (CGR). The document length (5162 characters) and detailed procedural content support this classification rather than a brief announcement or report publication.
2025-12-08 Chinese
国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司归还前次临时补充流动资金的闲置募集资金并继续使用部分闲置募集资金临时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guotai Huatong Securities regarding the verification and opinions on the use and repayment of idle raised funds temporarily supplementing working capital by Maiwei (Shanghai) Biotechnology Co., Ltd. It references regulatory rules related to the management and supervision of raised funds, details the amounts raised, usage plans, approvals by the board and supervisory committee, and the sponsor's verification opinion. The document is not a full annual or interim financial report but a specialized verification and opinion report related to the use of raised funds. It is not a simple announcement or certification but contains substantive content on the use of capital and compliance with regulations. This fits the definition of an Audit Report / Information (AR), which includes audit reports, applied accounting principles, and results of internal or regulatory checks excluding full annual reports. The document length (3363 characters) is relatively short but contains detailed verification and opinion content, not just an announcement of a report. Therefore, the best classification is AR with high confidence.
2025-12-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.